Home/Pipeline/Glutamate Modulator for Rett Syndrome

Glutamate Modulator for Rett Syndrome

Rett Syndrome

Licensed/Orphan DesignationActive

Key Facts

Indication

Rett Syndrome

Phase

Licensed/Orphan Designation

Status

Active

Company

Numedicus

About Numedicus

Numedicus is a private, UK-based biotech firm specializing in the systematic identification of new uses for existing drugs through its extensive, experimentally validated database. Founded in 2015, the company employs a virtual model, collaborating with partners to advance repurposed candidates through clinical development, as evidenced by its portfolio of licensed programs. Led by industry veteran David Cavalla, Numedicus targets significant unmet medical needs across diverse therapeutic areas, offering a de-risked and capital-efficient approach to drug development.

View full company profile

Therapeutic Areas

Rare Diseases Oncology Supportive Care Infectious Disease Neurology

Other Rett Syndrome Drugs

Drug	Company	Phase	Status
NTI164	Neurotech International	Phase 2	Active
RTT1	Grann Pharmaceuticals	Pre-clinical	Active
NEX-1 / NEX-2	Nexien BioPharma	Pre-clinical / Phase 1	Active
KIT-13	NeuroCores	Pre-clinical	Active
DPM-1003	DepYmed	Phase 1	Active
ExoEdit® for Rett Syndrome	Evox Therapeutics	Pre-clinical	Active
RVL-001 (vorinostat)	Unravel Biosciences	Clinical Trial Initiated	Active
Rett Syndrome Program	Herophilus	Discovery	Active
TTI-0102	Thiogenesis Therapeutics	Phase 1	Planned
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Approved	Commercial
TSHA-102	Taysha Gene Therapies	Phase 1/2	Active (Pivotal-Enabling)
Sarizotan	Newron Pharmaceuticals	Phase III	Discontinued